大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展

doi:10.35541/cjd.20200179

Abstract

Abstract: 【Abstract】 High-dose intravenous immunoglobulin （IVIG） has emerged as an effective treatment option for some refractory and severe dermatoses with few adverse reactions. The Fab and Fc fragments of IgG can exert anti-inflammatory effect by mediating specific downstream reactions via binding to a variety of autoantigens, autoantibodies and complements. This review summarizes action mechanisms of IVIG, focuses on the progress towards its application in severe dermatoses (such as severe drug eruption, refractory dermatomyositis and autoimmune bullous diseases) and special populations, as well as its adverse reactions.

Key words: Immunoglobulins, intravenous, Skin diseases, Severe dermatoses

Li Danqi, Lou Yuchen, Tao Juan. Application of high-dose intravenous immunoglobulin therapy in severe dermatoses[J]. Chinese Journal of Dermatology, 2022, 55(5): 455-459.doi:10.35541/cjd.20200179

References ［38］

［1］	Emre S. Intravenous immunoglobulin treatment: where do dermatologists stand?［J］. Dermatol Ther, 2019,32（3）:e12854. doi: 10.1111/dth.12854.
［2］	Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence［J］. J Allergy Clin Immunol, 2017,139（3S）:S1⁃S46. doi: 10.1016/j.jaci. 2016.09.023.
［3］	Liu P, Li L, Fan P, et al. High⁃dose of intravenous immunoglobulin modulates immune tolerance in premature infants［J］. BMC Pediatr, 2018,18（1）:74. doi: 10.1186/s12887⁃018⁃1055⁃5.
［4］	Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology⁃⁃mode of action and clinical efficacy［J］. Nat Rev Neurol, 2015,11（2）:80⁃89. doi: 10.1038/nrneurol.2014.253.
［5］	Mimouni D, Blank M, Payne AS, et al. Efficacy of intravenous immunoglobulin （IVIG） affinity⁃purified anti⁃desmoglein anti⁃idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris［J］. Clin Exp Immunol, 2010,162（3）:543⁃549. doi: 10.1111/j.1365⁃2249.2010.04265.x.
［6］	Bayry J, Kaveri SV. Kill ′Em All: Efgartigimod immunotherapy for autoimmune diseases［J］. Trends Pharmacol Sci, 2018,39（11）:919⁃922. doi: 10.1016/j.tips.2018.08.004.
［7］	Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis［J］. Neurology, 2019,92（23）:e2661⁃e2673. doi: 10.1212/WNL. 0000000000007600.
［8］	Teeling JL, Jansen⁃Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia［J］. Blood, 2001,98（4）:1095⁃1099. doi: 10. 1182/blood.v98.4.1095.
［9］	Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation［J］. J Clin Invest, 2019,129（9）:3492⁃3498. doi: 10.1172/JCI130029.
［10］	Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease［J］. Cell, 2018,172（3）:564⁃577.e13. doi: 10.1016/j.cell.2017.11.041.
［11］	Enk A, Hadaschik E, Eming R, et al. European Guidelines （S1） on the use of high⁃dose intravenous immunoglobulin in dermatology［J］. J Dtsch Dermatol Ges, 2017,15（2）:228⁃241. doi: 10.1111/ddg.13013.
［12］	Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens⁃Johnson syndrome: a retrospective comparative study in China［J］. Int J Dermatol, 2009,48（10）:1122⁃1128. doi: 10.1111/j.1365⁃4632.2009.04166.x.
［13］	White KD, Abe R, Ardern⁃Jones M, et al. SJS/TEN 2017: Building multidisciplinary networks to drive science and translation［J］. J Allergy Clin Immunol Pract, 2018,6（1）:38⁃69. doi: 10.1016/j.jaip.2017.11.023.
［14］	Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis with meta⁃regression of observational studies［J］. Int J Dermatol, 2015,54（1）:108⁃115. doi: 10.1111/ijd.12423.
［15］	Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2012,167（2）:424⁃432. doi: 10.1111/j.1365⁃2133.2012.10965.x.
［16］	中国医师协会皮肤科医师分会变态反应性疾病专业委员会. 药物超敏反应综合征诊治专家共识［J］. 中华皮肤科杂志, 2018,51（11）:787⁃790. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 11.002.
［17］	Shiohara T, Mizukawa Y. Drug⁃induced hypersensitivity syndrome （DiHS）/drug reaction with eosinophilia and systemic symptoms （DRESS）: An update in 2019［J］. Allergol Int, 2019,68（3）:301⁃308. doi: 10.1016/j.alit.2019.03.006.
［18］	朱伟芳, 李炎冬, 斯子翔, 等. 静脉注射丙种球蛋白和糖皮质激素治疗药物超敏综合征的疗效观察［J］. 中华急诊医学杂志, 2013,22（9）:1054⁃1056. doi: 10.3760/cma.j.issn.1671⁃0282. 2013.09.031.
［19］	Galimberti F, Kooistra L, Li Y, et al. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis［J］. Clin Exp Dermatol, 2018,43（8）:906⁃912. doi: 10.1111/ced. 13607.
［20］	Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology［J］. J Dtsch Dermatol Ges, 2016,14（3）:321⁃338. doi: 10.1111/ddg.12909.
［21］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［22］	Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585.e1. doi: 10.1016/ j.jaad.2018.02.021.
［23］	Gürcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety［J］. Am J Clin Dermatol, 2010,11（5）:315⁃326. doi: 10.2165/11533290⁃00000 0000⁃00000.
［24］	Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017［J］. Br J Dermatol, 2017,177（5）:1170⁃1201. doi: 10.1111/bjd.15930.
［25］	Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous immunoglobulin［J］. Front Immunol, 2018,9:1189. doi: 10.3389/fimmu.2018.01189.
［26］	Ahmed AR, Shetty S, Kaveri S, et al. Treatment of recalcitrant bullous pemphigoid （BP） with a novel protocol: a retrospective study with a 6⁃year follow⁃up［J］. J Am Acad Dermatol, 2016,74（4）:700⁃708.e3. doi: 10.1016/j.jaad.2015.11.030.
［27］	Ahmed AR, Nguyen T, Kaveri S, et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow⁃up［J］. Int Immunopharmacol, 2016,34:25⁃31. doi: 10.1016/j.intimp.2016.02.013.
［28］	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南［J］. 中华内科杂志, 2020,59（3）:172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002.
［29］	Nieto⁃Aristizábal I, Martínez T, Urbano MA, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single⁃center experience with 63 patients［J］. Lupus, 2019,28（13）:1566⁃1570. doi: 10.1177/0961203319883 680.
［30］	Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases［J］. Rheumatology （Oxford）, 2015,54（3）:383⁃391. doi: 10.1093/rheumatology/keu429.
［31］	Wong PH, White KM. Impact of Immunoglobulin therapy in pediatric disease: a review of immune mechanisms［J］. Clin Rev Allergy Immunol, 2016,51（3）:303⁃314. doi: 10.1007/s12016⁃015⁃8499⁃2.
［32］	Jee SJ, Kim JH, Baek HS, et al. Long⁃term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis［J］. Allergy Asthma Immunol Res, 2011,3（2）:89⁃95. doi: 10.4168/aair.2011.3.2.89.
［33］	Rademaker M, Agnew K, Andrews M, et al. Managing atopic dermatitis with systemic therapies in adults and adolescents: an Australian/New Zealand narrative［J］. Australas J Dermatol, 2020,61（1）:9⁃22. doi: 10.1111/ajd.13141.
［34］	Tekin B, Yücelten AD. Infantile bullous pemphigoid treated using intravenous immunoglobulin: case report and review of the literature［J］. Pediatr Dermatol, 2015,32（5）:723⁃726. doi: 10. 1111/pde.12635.
［35］	Kushner CJ, Concha J, Werth VP. Treatment of autoimmune bullous disorders in pregnancy［J］. Am J Clin Dermatol, 2018,19（3）:391⁃403. doi: 10.1007/s40257⁃018⁃0342⁃0.
［36］	Ahmed AR, Gürcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris［J］. J Eur Acad Dermatol Venereol, 2011,25（9）:1073⁃1079. doi: 10.1111/j.1468⁃3083.2010.03925.x.
［37］	Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy［J］. Front Immunol, 2018,9:1299. doi: 10.3389/fimmu. 2018.01299.
［38］	Hoffmann J, Enk AH. High⁃Dose Intravenous immunoglobulin in skin autoimmune disease［J］. Front Immunol, 2019,10:1090. doi: 10.3389/fimmu.2019.01090.

[1]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[2]	Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.
[3]	Zhang Guoyi, Gong Xiangdong, Zhu Bokun, Liu Chuanxia, Jing Linghua, Xu Jinyu. Patterns of skin diseases among outpatients attending Hospital of Dermatology of Chinese Academy of Medical Sciences in 2019 [J]. Chinese Journal of Dermatology, 2022, 55(2): 150-152.
[4]	You Ruixuan, Zeng Zhuotong, Qiu Xiangning, Xiao Rong. Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases: from basic research to clinical application [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210232-e20210232.
[5]	Jiang Peiyu, Zhang Jiawen, Liu Zijing, Wang Xiaoyan, Liu Yunyi, Liu Yixuan, Xu Yang. Basic principles of photobiomodulation and its application in dermatology [J]. Chinese Journal of Dermatology, 2022, 55(1): 84-87.
[6]	Chinese Society of Dermatology, China Dermatologist Association. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases （2022） [J]. Chinese Journal of Dermatology, 2022, 55(1): 1-11.
[7]	Long Hai, Jiang Li, Qiu Yueqi, Yao Nan, Liu Licong, Xie Yuming, Xiong Feng, Tan Siqi, Kuang Qiqi, You Ruixuan, Chai Ke, Luo Xin, Long Haojun, Xin Yue, Guo Ziyu, Wang Jiaqi, Tan Yixin, Zhang Qing, Zhang Guiying, Li Yaping, Su Yuwen, Xiao Rong, Lu Qianjin, . Clinical analysis of 1 057 patients with critical illnesses in a dermatological ward [J]. Chinese Journal of Dermatology, 2021, 54(9): 790-797.
[8]	Autoimmune Disease Group, China Dermatologist Association. Chinese expert consensus on cyclophosphamide for the treatment of autoimmune dermatoses [J]. Chinese Journal of Dermatology, 2021, 54(9): 765-770.
[9]	Hu Feng, Chen Liuqing, Wang Wei, Zheng Fang. Epidemiological characteristics and disease spectrum analysis of outpatients in the dermatology department of a hospital in Wuhan during the COVID-19 epidemic [J]. Chinese Journal of Dermatology, 2021, 54(8): 719-722.
[10]	Ying Jieya, Xiang Wenzhong, Song Xiuzu. Metabolic syndrome and skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(7): 642-645.
[11]	Committee on Autoimmune Diseases, China Dermatologist Association. Expert consensus on methotrexate in the treatment of immune-associated dermatoses [J]. Chinese Journal of Dermatology, 2021, 54(5): 382-390.
[12]	Ye Ruixian, Xue Rujun, Liang Jingyao, Liu Huanyan, Xiong Qiying, Dong Liangjiao, Zhang Xibao. Role of microRNAs in inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(2): 178-182.
[13]	Liu Pei, Shi Lei, Wang Xiuli. Selection of light sources and radiation parameters in photodynamic therapy for skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(11): 1015-1018.
[14]	Zhu Beibei, Li Jing, Huang Huiyao, Li Ning, Liu Lijun, Zhang Lihua, Huan Jing, Ni Qi, Hou Wei, Liu Yi, Yang Xueyuan. Analysis of clinical trials of dermatological drugs in China, 2020 [J]. Chinese Journal of Dermatology, 2021, 54(11): 1001-1004.
[15]	Zheng Yucan, Kong Guiping, Jin Yu, Li Mei. A case of hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis caused by a mutation in the FAM111B gene [J]. Chinese Journal of Dermatology, 2021, 54(11): 973-977.

Application of high-dose intravenous immunoglobulin therapy in severe dermatoses

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［38］

Related Articles 15

Metrics

Comments

Recommended 10